Expression of DNA Topoisomerase II and P-Glycoprotein in Breast Cancer.
- Author:
Hye Rim PARK
1
;
Eun Ha JUNG
;
Jin Hee SOHN
;
Young Euy PARK
Author Information
1. Department of Pathology, College of Medicine, Hallym University, Korea.
- Publication Type:Original Article
- Keywords:
DNA topoisomerase II;
P-glycoprotein;
Breast cancer;
Immunohistochemistry
- MeSH:
Breast Neoplasms*;
Breast*;
DNA Topoisomerases, Type I*;
DNA Topoisomerases, Type II*;
DNA*;
Follow-Up Studies;
Humans;
Immunohistochemistry;
Lymph Nodes;
Neoplasm Metastasis;
P-Glycoprotein*;
Retrospective Studies;
Tamoxifen
- From:Journal of the Korean Cancer Association
1997;29(2):242-249
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To determine whether the expression of DNA topoisomerase II and P-glycoprotein are of prognostic value. MATERIALS AND METHODS: We evaluated the expression of DNA topoisomerase II and P-glycoprotein immunohistochemically in a retrospective study of samples from 44 patients with breast cancer. Thirty two among 44 patients (72.7%) received chemotherapeutic treatments (CMF or FAC protocol) and/or tamoxifen postoperatively. RESULTS: P-glycoprotein was detected in the 27 samples of 44 patients (61.3%). The expression of P-glycoprotein was increased in the patients older than 50 years, with distant metastases, and with death on follow-up. DNA topoisomerase II was detected in the 34 samples of 44 patients (77.2%). The expression of topoisomerase II was increased in the patients younger than 50 years, with recurrent tumor, with distant metastases, and with death on follow-up. The expression of P-glycoprotein and topoisomerase II was not correlated with other clinico-pathological factors including the size of primary tumor, involvement of lymph node, histologic grade, and clinical stage. The correlation between expression of P-glycoprotein and topoisomerase II was not significant. CONCLUSION: The immunohistochemical evaluation of P-glycoprotein and topoisomerase II before treatment in breast cancer has little clinical prognostic value.